Darexaban (maleate)

Darexaban maleate (YM150 maleate) is a direct factor Xa inhibitor with activity in preventing venous thromboembolism. The major metabolite of Darexaban maleate in humans is Darexaban glucitol, which acts pharmacologically. The glucitolation reaction of Darexaban maleate is mainly catalyzed by UGT1A9 and UGT1A10 in the human liver and intestine. The K (m) value of Darexaban maleate glucitolation in the liver is greater than 250 μM, while in the intestine it exhibits substrate inhibition kinetics with a K (m) value of 27.3 μM. The unbound K (m) value of Darexaban maleate is significantly reduced by the influence of fatty acid-free bovine serum albumin in both HLM and UGT1A9[1].

Product Specifications

CAS Number

[365462-24-4]

Product Name Alternative

YM150 (maleate)

UNSPSC

12352005

Target

Endogenous Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/darexaban-maleate.html

Smiles

OC(/C=C\C(O)=O)=O.O=C(C1=CC=C(N2CCCN(CC2)C)C=C1)NC3=C(C=CC=C3O)NC(C4=CC=C(C=C4)OC)=O

Molecular Formula

C31H34N4O8

Molecular Weight

590.62

References & Citations

[1]Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine